{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-014595","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.960652+00:00","generated_at":"2026-06-15T02:01:31.741313+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Windtree Q1 net loss $4.1M; runway extended via $10.8M offering; EU patent granted","bullets":["Net loss $4.1M ($4.76/sh) vs $8.1M in Q1 2022; operating loss narrowed to $4.2M from $8.3M.","Cash $4.2M as of Mar 31; April public offering raised $10.8M net, funding through Q1 2024.","R&D expense fell 74% to $1.4M; G&A down 23% to $2.3M; average monthly cash burn cut 58% YoY.","European Patent Office granted SERCA2a activator patent coverage through July 2038.","Regained Nasdaq minimum bid price compliance; publication on istaroxime cardiogenic shock dose-response."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-014595","json":"https://secwatch.observer/filing/0001437749-23-014595.json","markdown":"https://secwatch.observer/filing/0001437749-23-014595.md","text":"https://secwatch.observer/filing/0001437749-23-014595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/0001437749-23-014595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/wint20230412_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:01:31.741313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9dfca80a83adff4b13481f5fa9b45709e5734390","claim":"WINDTREE THERAPEUTICS INC /DE/ reported quarter ended March 31, 2023 results: net income net loss of $4.1 million, EPS $4.76 per basic share.","evidence_excerpt":"The Company reported a net loss of $4.1 million ( $4.76 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended March 31, 2023 , compared to a net loss of $8.1 million ( $14.36 per basic share) on 0.6 million weighted average common shares outstanding for the comparable period in 2022 .","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/0001437749-23-014595-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of $4.1 million"},{"label":"EPS","value":"$4.76 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}